Editas Medicine Inc
Ownership
Ownership Structure
Who owns Editas Medicine Inc (EDIT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 75.2% of the shares are freely tradable; institutional investors hold 49.4%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 7.23 | 11,111,111 | +0.0 | 06/30/2026 |
| BlackRock Inc | 6.90 | 10,589,990 | +14.3 | 06/30/2026 |
| COMMODORE CAPITAL LP | 5.79 | 8,889,000 | +0.0 | 06/30/2026 |
| RA Capital Management, LLC | 5.79 | 8,889,000 | +0.0 | 06/30/2026 |
| ADAR1 Capital Management LLC | 5.79 | 8,889,000 | +0.0 | 06/30/2026 |
| Vanguard Capital Management, LLC | 4.00 | 6,141,336 | +46.1 | 06/30/2026 |
| Paradigm Biocapital Advisors LP | 3.64 | 5,586,625 | +0.0 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.86 | 4,390,864 | -10.2 | 09/30/2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.77 | 4,257,072 | -1.9 | 09/30/2026 |
| iShares Russell 2000 ETF | 2.59 | 3,980,089 | -1.1 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| O'Neill Gilmore Neil | CEO | 243,189 | 656,610 $ | Sep 3, 2026 | direct |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 61,660 | 166,482 $ | Sep 3, 2026 | direct |
| Parison Amy | SVP, Chief Financial Officer | 13,839 | 37,365 $ | Sep 3, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | Parison Amy | SVP, Chief Financial Officer | Sell | 453 | 3.04 | 1,376 |
| Sep 3, 2026 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 709 | 3.04 | 2,153 |
| Sep 3, 2026 | O'Neill Gilmore Neil | CEO | Sell | 5,124 | 3.04 | 15,563 |
| Aug 3, 2026 | Parison Amy | SVP, Chief Financial Officer | Sell | 678 | 2.58 | 1,749 |
| Jul 28, 2026 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 4,928 | 2.67 | 13,158 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.